Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.

By L. Wallentin, S. James, Robert F. Storey, M. Armstrong, B. Barratt, J. Horrow, S. Husted, H. Katus, P. Steg, Svati H. Shah and 1 more. The Lancet, 2010

809 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Hematology, Pharmacology

View Paper: https://www.semanticscholar.org/paper/3055481994e7c57a325492cb4313a8354dff9b1a

Citations in the corpus

• Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI: A Meta-Analysis (2010, neutral): “A computerized literature search was conducted from January 2000 through August 2010 of MEDLINE, Cochrane Database of Systematic Reviews, and EMBASE using the search terms clopidogrelandCYP2C19.”